The accuracy of lipid accumulation product to predict metabolic syndrome in PCOS: a meta-analysis and comparative analysis with other indicators - Summary - MDSpire
Advertisement
The accuracy of lipid accumulation product to predict metabolic syndrome in PCOS: a meta-analysis and comparative analysis with other indicators
To examine the accuracy of the lipid accumulation product (LAP) in screening for metabolic syndrome (MetS) among patients with polycystic ovary syndrome (PCOS) and compare it with other predictive metrics.
Key Findings:
LAP was significantly elevated in PCOS patients with MetS, with a pooled mean difference of 2.52 units (P<0.001).
LAP showed a strong association with MetS, yielding a pooled odds ratio of 34.31 (P<0.001).
For detecting MetS, LAP exhibited a pooled sensitivity of 87% (95% CI: 79%–92%), specificity of 84% (95% CI: 79%–89%), and an AUROC of 0.92 (95% CI: 0.89–0.94).
The AUROC of LAP was significantly superior to that of BMI, waist circumference, triglyceride levels, and abdominal volume index (P<0.001).
Interpretation:
LAP is a cost-effective and simple indicator for screening MetS in the PCOS population, suggesting its potential to enhance early detection and management compared to traditional metrics.
Limitations:
Potential variability in study designs and populations included in the meta-analysis may affect the generalizability of the findings.
Limited number of studies specifically addressing LAP in PCOS.
Conclusion:
LAP is a better proxy indicator for screening MetS in PCOS patients, facilitating early detection and management of associated health risks.
